NASDAQ:CLDX Celldex Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $28.69 -0.45 (-1.54%) (As of 06/28/2022 04:00 PM ET) Add Compare Share Today's Range$28.02▼$29.5550-Day Range$20.50▼$34.6352-Week Range$19.85▼$57.20Volume827,236 shsAverage Volume627,152 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$65.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Stock Forecast (MarketRank)Overall MarketRank™2.03 out of 5 starsMedical Sector564th out of 1,433 stocksDiagnostic Substances Industry7th out of 27 stocksAnalyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingCelldex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.00, Celldex Therapeutics has a forecasted upside of 126.6% from its current price of $28.69.Amount of Analyst CoverageCelldex Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesCelldex Therapeutics has received 585 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCelldex Therapeutics has received 190 “underperform” votes. (Add your “underperform” vote.)Community SentimentCelldex Therapeutics has received 75.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote “Outperform” if you believe CLDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.90% of the stock of Celldex Therapeutics is held by insiders.Percentage Held by Institutions98.61% of the stock of Celldex Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.00) to ($2.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -16.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -16.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Celldex Therapeutics (NASDAQ:CLDX)Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.Read More CLDX Stock News HeadlinesJune 24, 2022 | americanbankingnews.comFY2022 EPS Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX) Increased by AnalystJune 22, 2022 | finance.yahoo.comCelldex (CLDX) Initiates Phase II Chronic Skin Disorder StudyJune 21, 2022 | finance.yahoo.comCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous UrticariaJune 20, 2022 | finance.yahoo.comWe're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash WiselyJune 16, 2022 | finance.yahoo.comCelldex Announces Two New Appointments to its Board of DirectorsJune 15, 2022 | americanbankingnews.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Buy" by BrokeragesJune 12, 2022 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week Low at $21.15June 10, 2022 | americanbankingnews.comCelldex Therapeutics, Inc. to Post FY2023 Earnings of ($2.26) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CLDX)June 9, 2022 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Up to $23.65June 6, 2022 | finance.yahoo.comCelldex to Present at the 2022 Jefferies Global Healthcare ConferenceJune 5, 2022 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Shares Up 3.8%June 1, 2022 | nasdaq.comCelldex Therapeutics Becomes Oversold (CLDX)May 19, 2022 | finance.yahoo.comCelldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLDX CUSIP15117B10 CIK744218 Webwww.celldex.com Phone(908) 200-7500Fax908-454-1911Employees132Year Founded1983Company Calendar Last Earnings5/05/2022Today6/28/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$65.00 High Stock Price Forecast$68.00 Low Stock Price Forecast$60.00 Forecasted Upside/Downside+126.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.710010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70.51 million Net Margins-1,860.46% Pretax Margin-1,865.94% Return on Equity-20.68% Return on Assets-19.37% Debt Debt-to-Equity RatioN/A Current Ratio26.83 Quick Ratio26.83 Sales & Book Value Annual Sales$4.65 million Price / Sales288.47 Cash FlowN/A Price / Cash FlowN/A Book Value$8.99 per share Price / Book3.19Miscellaneous Outstanding Shares46,754,000Free Float45,866,000Market Cap$1.34 billion OptionableOptionable Beta2.72 Social Links Celldex Therapeutics Frequently Asked Questions Should I buy or sell Celldex Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Celldex Therapeutics stock. View analyst ratings for Celldex Therapeutics or view top-rated stocks. What is Celldex Therapeutics' stock price forecast for 2022? 5 analysts have issued 12-month price objectives for Celldex Therapeutics' stock. Their CLDX stock forecasts range from $60.00 to $68.00. On average, they predict Celldex Therapeutics' stock price to reach $65.00 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price. View analysts' price targets for Celldex Therapeutics or view top-rated stocks among Wall Street analysts. How has Celldex Therapeutics' stock price performed in 2022? Celldex Therapeutics' stock was trading at $38.64 at the beginning of 2022. Since then, CLDX shares have decreased by 25.8% and is now trading at $28.69. View the best growth stocks for 2022 here. When is Celldex Therapeutics' next earnings date? Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Celldex Therapeutics. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.75 million. Celldex Therapeutics had a negative net margin of 1,860.46% and a negative trailing twelve-month return on equity of 20.68%. View Celldex Therapeutics' earnings history. When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work? Celldex Therapeutics shares reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' key executives? Celldex Therapeutics' management team includes the following people: Mr. Anthony S. Marucci M.B.A., Founder, Pres, CEO & Director (Age 60, Pay $1.18M)Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 63, Pay $748.51k)Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 51, Pay $619.35k)Mr. Freddy A. Jimenez Esq., Sr. VP & Gen. Counsel (Age 53, Pay $579.7k) (LinkedIn Profile)Dr. Diane C. Young M.D., Sr. VP & Chief Medical Officer (Age 65, Pay $636k)Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin. (Age 47) (LinkedIn Profile)Patrick Till, Sr. Director of Investor Relations & Corp. CommunicationsDr. Ronald A. Pepin, Chief Bus. Officer & Sr. VP (Age 66)Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 50) (LinkedIn Profile)Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 58) Who are some of Celldex Therapeutics' key competitors? Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of CLDX's competitors. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX). What is Celldex Therapeutics' stock symbol? Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX." Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.55%), RTW Investments LP (6.60%), BlackRock Inc. (6.52%), State Street Corp (5.74%), Vanguard Group Inc. (5.21%) and RA Capital Management L.P. (4.44%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler. View institutional ownership trends for Celldex Therapeutics. Which institutional investors are selling Celldex Therapeutics stock? CLDX stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Invesco Ltd., Candriam Luxembourg S.C.A., BlackRock Inc., Ghost Tree Capital LLC, First Trust Advisors LP, Northern Trust Corp, and Kiwi Wealth Investments Limited Partnership. Company insiders that have sold Celldex Therapeutics company stock in the last two years include Diane C Young, Elizabeth Crowley, Richard M Wright, Samuel Bates Martin, and Sarah Cavanaugh. View insider buying and selling activity for Celldex Therapeutics or view top insider-selling stocks. Which institutional investors are buying Celldex Therapeutics stock? CLDX stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Viking Global Investors LP, Kynam Capital Management LP, Woodline Partners LP, State Street Corp, RA Capital Management L.P., Polar Capital Holdings Plc, and Sessa Capital IM L.P.. View insider buying and selling activity for Celldex Therapeutics or or view top insider-buying stocks. How do I buy shares of Celldex Therapeutics? Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celldex Therapeutics' stock price today? One share of CLDX stock can currently be purchased for approximately $28.69. How much money does Celldex Therapeutics make? Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.34 billion and generates $4.65 million in revenue each year. The biopharmaceutical company earns $-70.51 million in net income (profit) each year or ($1.710010) on an earnings per share basis. How many employees does Celldex Therapeutics have? Celldex Therapeutics employs 132 workers across the globe. When was Celldex Therapeutics founded? Celldex Therapeutics was founded in 1983. How can I contact Celldex Therapeutics? Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for Celldex Therapeutics is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at [email protected], or via fax at 908-454-1911. This page (NASDAQ:CLDX) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here